PT - JOURNAL ARTICLE AU - Lewnard, Joseph A. AU - Hong, Vennis AU - Tartof, Sara Y. TI - Association of SARS-CoV-2 BA.4/BA.5 Omicron lineages with immune escape and clinical outcome AID - 10.1101/2022.07.31.22278258 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.31.22278258 4099 - http://medrxiv.org/content/early/2022/08/02/2022.07.31.22278258.short 4100 - http://medrxiv.org/content/early/2022/08/02/2022.07.31.22278258.full AB - Expansion of the SARS-CoV-2 BA.4/BA.5 Omicron lineages in populations with prevalent immunity from prior infection and vaccination has raised concerns about the association of these lineages with immune escape. Here we show that COVID-19 vaccination and documented prior infection are associated with reduced protection against infection with BA.4/BA.5. Compared to time-matched BA.2 cases, BA.4/BA.5 cases had 9% (95% confidence interval: 2-17%) and 27% (15-41%) higher adjusted odds of having received 3 and 4 COVID-19 vaccine doses, respectively, and 55% (39-71%) higher adjusted odds of documented infection ≥90 days previously. However, BA.4/BA.5 infection was not associated with differential risk of emergency department presentation, hospital admission, or intensive care unit admission following an initial outpatient diagnosis. This finding held after correcting for potential exposure misclassification resulting from unascertained prior infections. Despite increased risk of BA.4/BA.5 breakthrough infection observed among previously vaccinated or infected individuals, the reduced severity associated with prior (BA.1 and BA.2) Omicron lineages has persisted with BA.4/BA.5.Competing Interest StatementJAL has received research grants and consulting honoraria unrelated to this study from Pfizer. SYT has received research grants unrelated to this study from Pfizer. VH discloses no competing interests.Funding StatementThis work was funded by the US Centers for Disease Control and Prevention (CDC). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. JAL was supported by grant R01-AI14812701A1 from the National Institute for Allergy and Infectious Diseases (US National Institutes of Health) which had no role in design or conduct of the study, or decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Kiaser Permanente Southern California Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual level clinical data are not publicly available for sharing.